Baird on Lineage Cell Therapeutics Inc. (LCTX): 'Incrementally positive following partner's R&D Day'
-
Lineage partners with William Demant Invest on hearing loss therapy
-
Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 10c, Beats on Revenue
-
H.C. Wainwright Reiterates Buy Rating on Lineage Cell Therapeutics Inc. (LCTX)
-
Lineage Cell Therapeutics (LCTX) Tops Q1 EPS by 1c
-
Lineage Cell Therapeutics Inc. (LCTX) PT Lowered to $3 at Craig-Hallum
-
Lineage Cell Therapeutics (LCTX) Tops Q4 EPS by 2c
-
Lineage Cell Therapeutics (LCTX) Issues Letter to Stockholders
-
Lineage Cell Therapeutics Inc. (LCTX) PT Raised to $9 at H.C. Wainwright
-
Lineage Cell Therapeutics (LCTX) Prices Up to $66M Share and Warrant Offering
-
D. Boral Capital Starts Lineage Cell Therapeutics Inc. (LCTX) at Buy
-
Baird Reiterates Outperform Rating on Lineage Cell Therapeutics Inc. (LCTX)
-
Craig-Hallum Starts Lineage Cell Therapeutics Inc. (LCTX) at Buy
-
Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 3c

